|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBM18 |
Gene summary for RBM18 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBM18 | Gene ID | 92400 |
| Gene name | RNA binding motif protein 18 | |
| Gene Alias | RBM18 | |
| Cytomap | 9q33.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q96H35 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 92400 | RBM18 | LZE2T | Human | Esophagus | ESCC | 1.68e-02 | 4.65e-01 | 0.082 |
| 92400 | RBM18 | LZE4T | Human | Esophagus | ESCC | 5.63e-13 | 3.27e-01 | 0.0811 |
| 92400 | RBM18 | LZE8T | Human | Esophagus | ESCC | 2.97e-08 | 1.79e-01 | 0.067 |
| 92400 | RBM18 | LZE20T | Human | Esophagus | ESCC | 2.92e-14 | 4.55e-01 | 0.0662 |
| 92400 | RBM18 | LZE22T | Human | Esophagus | ESCC | 5.47e-06 | 1.83e-01 | 0.068 |
| 92400 | RBM18 | LZE24T | Human | Esophagus | ESCC | 5.18e-14 | 3.30e-01 | 0.0596 |
| 92400 | RBM18 | LZE6T | Human | Esophagus | ESCC | 2.32e-14 | 2.58e-01 | 0.0845 |
| 92400 | RBM18 | P1T-E | Human | Esophagus | ESCC | 1.34e-04 | 1.26e-01 | 0.0875 |
| 92400 | RBM18 | P2T-E | Human | Esophagus | ESCC | 7.53e-25 | 4.07e-01 | 0.1177 |
| 92400 | RBM18 | P4T-E | Human | Esophagus | ESCC | 2.97e-25 | 4.83e-01 | 0.1323 |
| 92400 | RBM18 | P5T-E | Human | Esophagus | ESCC | 1.25e-12 | 1.94e-01 | 0.1327 |
| 92400 | RBM18 | P8T-E | Human | Esophagus | ESCC | 2.66e-18 | 3.50e-01 | 0.0889 |
| 92400 | RBM18 | P9T-E | Human | Esophagus | ESCC | 8.95e-16 | 2.82e-01 | 0.1131 |
| 92400 | RBM18 | P10T-E | Human | Esophagus | ESCC | 2.51e-21 | 3.09e-01 | 0.116 |
| 92400 | RBM18 | P11T-E | Human | Esophagus | ESCC | 1.79e-09 | 3.31e-01 | 0.1426 |
| 92400 | RBM18 | P12T-E | Human | Esophagus | ESCC | 3.28e-15 | 2.68e-01 | 0.1122 |
| 92400 | RBM18 | P15T-E | Human | Esophagus | ESCC | 1.01e-18 | 4.64e-01 | 0.1149 |
| 92400 | RBM18 | P16T-E | Human | Esophagus | ESCC | 4.89e-12 | 2.67e-01 | 0.1153 |
| 92400 | RBM18 | P17T-E | Human | Esophagus | ESCC | 1.16e-13 | 3.32e-01 | 0.1278 |
| 92400 | RBM18 | P19T-E | Human | Esophagus | ESCC | 2.64e-05 | 6.71e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBM18 | insertion | Nonsense_Mutation | novel | c.471_472insTAGCTGGGCGTGGTGGCACATGCCTGCAA | p.Asp158Ter | p.D158* | Q96H35 | protein_coding | TCGA-A8-A0A2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| RBM18 | SNV | Missense_Mutation | novel | c.38N>T | p.Ala13Val | p.A13V | Q96H35 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RBM18 | SNV | Missense_Mutation | novel | c.532N>G | p.Thr178Ala | p.T178A | Q96H35 | protein_coding | tolerated(0.23) | benign(0.003) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBM18 | SNV | Missense_Mutation | c.208G>T | p.Gly70Cys | p.G70C | Q96H35 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RBM18 | SNV | Missense_Mutation | novel | c.77N>A | p.Arg26Gln | p.R26Q | Q96H35 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RBM18 | SNV | Missense_Mutation | c.137A>G | p.Gln46Arg | p.Q46R | Q96H35 | protein_coding | deleterious(0.04) | benign(0.403) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RBM18 | SNV | Missense_Mutation | novel | c.32N>T | p.Glu11Val | p.E11V | Q96H35 | protein_coding | deleterious(0.01) | possibly_damaging(0.637) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| RBM18 | SNV | Missense_Mutation | novel | c.329G>T | p.Arg110Ile | p.R110I | Q96H35 | protein_coding | deleterious(0.04) | benign(0.222) | TCGA-2Y-A9H9-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Targeted Molecular therapy | sorafenib | PD |
| RBM18 | SNV | Missense_Mutation | novel | c.32N>G | p.Glu11Gly | p.E11G | Q96H35 | protein_coding | deleterious(0.04) | benign(0.435) | TCGA-2Y-A9HA-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| RBM18 | SNV | Missense_Mutation | c.322G>T | p.Val108Leu | p.V108L | Q96H35 | protein_coding | tolerated(0.51) | benign(0.001) | TCGA-86-A456-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |